Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Our strategy is based on an integrated business model that has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
Upcoming Events
November 16, 2021
Jefferies London Healthcare Conference
November 18, 2021
9M 2021 Financial Results
H1 2021 Financial Results
Valneva Reports H1 2021 Financial Results and Provides Business Update
View MoreContact
Investor Relations Team
Campus Bio-Ouest6, Rue Alain Bombard
44800 Saint-Herblain, France T: +33 2 28 07 37 10 investors@valneva.com